Pemodelan Farmakokinetika Berbasis Populasi dengan R: Model Dua Kompartemen Ekstravaskuler: Population-Based Pharmacokinetics Modeling With R: Two Compartment Extravascular Model

A Tutorial of two-compartment extravascular population-based pharmacokinetics modeling was performed by differential equations and non-linear mixed effect model approach. First, three-level differential equations of two-compartment pharmacokinetics were generated. Then, covariate and non-covariate models were developed by nlmeODE and nlme packages installed in R. The best model was selected according to AIC, BIC, and LogLik value. A model without covariates model was selected as the best model. The selected model showed a goodness of fit with experimental dataset and residual plot of the model revealed that no violations of model assumtions.  In conclusion, nlme and nlmeODE is capable to generate an adequate predictive model of two-compartment population-based pharmacokinetics for extravascular rout

Oral activated charcoal prevents experimental cerebral malaria in mice and in a randomized controlled clinical trial in man did not interfere with the pharmacokinetics of parenteral artesunate.

BACKGROUND: Safe, cheap and effective adjunct therapies preventing the development of, or reducing the mortality from, severe malaria could have considerable and rapid public health impact. Oral activated charcoal (oAC) is a safe and well tolerated treatment for acute poisoning, more recently shown to have significant immunomodulatory effects in man. In preparation for possible efficacy trials in human malaria, we sought to determine whether oAC would i) reduce mortality due to experimental cerebral malaria (ECM) in mice, ii) modulate immune and inflammatory responses associated with ECM, and iii) affect the pharmacokinetics of parenteral artesunate in human volunteers. METHODS/PRINCIPAL FINDINGS: We found that oAC provided significant protection against P. berghei ANKA-induced ECM, increasing overall survival time compared to untreated mice (p<0.0001; hazard ratio 16.4; 95% CI 6.73 to 40.1). Protection from ECM by oAC was associated with reduced numbers of splenic TNF(+) CD4(+) T cells and multifunctional IFNgamma(+)TNF(+) CD4(+) and CD8(+) T cells. Furthermore, we identified a whole blood gene expression signature (68 genes) associated with protection from ECM. To evaluate whether oAC might affect current best available anti-malarial treatment, we conducted a randomized controlled open label trial in 52 human volunteers (ISRCTN NR. 64793756), administering artesunate (AS) in the presence or absence of oAC. We demonstrated that co-administration of oAC was safe and well-tolerated. In the 26 subjects further analyzed, we found no interference with the pharmacokinetics of parenteral AS or its pharmacologically active metabolite dihydroartemisinin. CONCLUSIONS/SIGNIFICANCE: oAC protects against ECM in mice, and does not interfere with the pharmacokinetics of parenteral artesunate. If future studies succeed in establishing the efficacy of oAC in human malaria, then the characteristics of being inexpensive, well-tolerated at high doses and requiring no sophisticated storage would make oAC a relevant candidate for adjunct therapy to reduce mortality from severe malaria, or for immediate treatment of suspected severe malaria in a rural setting. TRIAL REGISTRATION: Controlled-Trials.com ISRCTN64793756

Data-driven modelling of biological multi-scale processes

Biological processes involve a variety of spatial and temporal scales. A holistic understanding of many biological processes therefore requires multi-scale models which capture the relevant properties on all these scales. In this manuscript we review mathematical modelling approaches used to describe the individual spatial scales and how they are integrated into holistic models. We discuss the relation between spatial and temporal scales and the implication of that on multi-scale modelling. Based upon this overview over state-of-the-art modelling approaches, we formulate key challenges in mathematical and computational modelling of biological multi-scale and multi-physics processes. In particular, we considered the availability of analysis tools for multi-scale models and model-based multi-scale data integration. We provide a compact review of methods for model-based data integration and model-based hypothesis testing. Furthermore, novel approaches and recent trends are discussed, including computation time reduction using reduced order and surrogate models, which contribute to the solution of inference problems. We conclude the manuscript by providing a few ideas for the development of tailored multi-scale inference methods.Comment: This manuscript will appear in the Journal of Coupled Systems and Multiscale Dynamics (American Scientific Publishers

Physiological and pharmacological modelling in neurological intensive care and anaesthesia

Mathematical models of physiological processes can be used in critical care and anaesthesia to improve the understanding of disease processes and to guide treatment. This thesis provides a detailed description of two studies that are related through their shared aim of modelling different aspects of brain physiology. The Relationship Between Transcranial Bioimpedance and Invasive Intracranial Pressure Measurement in Traumatic Brain Injury Patients (BioTBI) Study describes an attempt to model intracranial pressure (ICP) in patients admitted with severe traumatic brain injury (TBI). It is introduced with a detailed discussion of the monitoring and modelling of ICP in patients with TBI alongside the rationale for considering transcranial bioimpedance (TCB) as a non-invasive approach to estimating ICP. The BioTBI Study confirmed a significant relationship between TCB and invasively measured ICP in ten patients admitted to the neurological intensive care unit (NICU) with severe TBI. Even when using an adjusted linear modelling technique to account for patient covariates, the magnitude of the relationship was small (r-squared = 0.32) and on the basis of the study, TCB is not seen as a realistic technique to monitor ICP in TBI. Target controlled infusion (TCI) of anaesthetic drugs exploit known pharmacokinetic pharmacodynamic (PKPD) models to achieve set concentrations in the plasma or an effect site. Following a discussion of PKPD model development for the anaesthetic drug propofol, the Validation Study of the Covariates Model (VaSCoM) describes a joint PKPD study of the Covariates Model. Pharmacokinetic validation of plasma concentrations predicted by the model in forty patients undergoing general anaesthesia confirmed a favourable overall bias (3%) and inaccuracy (25%) compared to established PKPD models. The first description of the pharmacodynamic behaviour of the Covariates Model is provided with an estimated rate constant for elimination from the effect site compartment (ke0) of 0.21 to 0.27 min-1